Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAT-PPCI
2011-005273-23Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2011
- Countries
- 1
- Sponsor
- Liverpool Heart and Chest Hospital
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Drugs
- bivalirudinheparin
- Conditions
- myocardial infarction (MI)
01
Overview
Phase 4, randomised, open-label trial in myocardial infarction (MI) comparing Bivalirudin with Heparin sodium (2 arms). Primary endpoint: Primary efficacy end point. Started Dec 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Bivalirudin
Patients randomized to bivalirudin during primary PCI
Heparin sodium
Patients randomized to unfractionated heparin during primary PCI
03
Who it enrols
Adults older than 18 years presenting to participating centres with ST-segment elevation myocardial infarction and planned management with primary percutaneous coronary intervention were eligible.
04
Endpoints
Primary
Primary efficacy end point
Secondary
Peak CKMB release following index revascularisation
Beyond the preview
Go deeper on 2011-005273-23.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005273-23.